CORONAVIRUS News & Analysis

Analysts expect the sector to recover to pre-Covid trading levels once borders reopen.

The veteran stock picker sees no shortage of risks including that covid-19 mutations could render current vaccines ineffective.

Covid outbreak unlikely to derail Australia’s impressive economic recovery but rate rises still some way off, writes Morningstar's Gareth James.

Investors who stood firm were rewarded as the markets recovered, and then some.

Morningstar has compiled a handy list of more than 150 companies under coverage that will release results this month.

Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

The plasma giant remains overvalued, according to Morningstar.

Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.

Energy stocks are on a tear and there's more to come, says Morningstar.

We believe Pfizer and BioNTech's vaccine is set up for emergency use this year, followed by full approval in 2021 pending supportive final data.